Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Ventilation -38% ICU admission -122% Progression -28% primary Paxlovid for COVID-19  Wei et al.  LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 725 patients in China (December 2022 - January 2023) Study compares with azvudine, results vs. placebo may differ Higher ventilation with paxlovid (p=0.039) c19early.org Wei et al., Frontiers in Pharmacology, Oct 2023 Favors paxlovid Favors azvudine

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Wei et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1274294
Oct 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
PSM retrospective 725 hospitalized COVID-19 patients in China compared the effectiveness and safety of the oral antivirals azvudine and paxlovid. There was no significant difference in the risk of disease progression between groups, but azvudine was associated with lower ICU admission and invasive ventilation use.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
Study covers paxlovid and azvudine.
risk of death, 0.2% lower, RR 1.00, p = 1.00, treatment 36 of 264 (13.6%), control 63 of 461 (13.7%), NNT 3381.
risk of mechanical ventilation, 38.3% higher, RR 1.38, p = 0.04, treatment 61 of 264 (23.1%), control 77 of 461 (16.7%).
risk of ICU admission, 122.2% higher, RR 2.22, p = 0.05, treatment 14 of 264 (5.3%), control 11 of 461 (2.4%).
risk of progression, 28.3% higher, RR 1.28, p = 0.07, treatment 72 of 264 (27.3%), control 98 of 461 (21.3%), ICU admission, invasive mechanical ventilation, and in-hospital death, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wei et al., 13 Oct 2023, retrospective, China, peer-reviewed, 8 authors, study period 1 December, 2022 - 31 January, 2023, this trial compares with another treatment - results may be better when compared to placebo. Contact: 13620327@qq.com, ld_2069@163.com.
This PaperPaxlovidAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit